Stock Scorer

Serina Therapeutics, Inc. (SER)

Serina Therapeutics, Inc. reported revenue of 0 USD for the quarter ending 30 June 2026.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 0 —
Gross Profit Q4 '23 · ending 31 December 2023 55K +685.7%
Operating Income Q2 '26 · ending 30 June 2026 -6.8M —
Net Income Q2 '26 · ending 30 June 2026 -6.4M —
Cost of Revenue Q4 '23 · ending 31 December 2023 1K +0.0%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -6.7M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -6.7M —
Shares Outstanding Q2 '26 · ending 30 June 2026 16.4M +67.9%
EPS Q2 '26 · ending 30 June 2026 -1.89 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 130K-24M-19.2M-18M
20242024-12-31 56K-17M-11.1M-17.2M
20232023-12-31 3.2M-3.1M5.3M-3M
20222022-12-31 34K-7M-10.5M—
20212021-12-31 144K-7.9M-8.7M—
20202020-12-31 361K-10.1M-10.9M-7.8M
20192019-12-31 1.7M-12.6M-12.2M-10.8M
20182018-12-31 1.4M-11.2M-7.5M-8M
20172017-12-31 1.4M-6.7M-6.6M-6.3M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-300
Q4 '252025-12-310
Q3 '252025-09-300
Q2 '252025-06-30130K
Q1 '252025-03-310
Q3 '242024-09-3014K
Q2 '242024-06-3051K
Q1 '242024-03-315K
Q4 '232023-12-313.1M
Q3 '232023-09-3029K
Q2 '232023-06-307K
Q1 '232023-03-3130K
Q4 '222022-12-318K
Q3 '222022-09-309K
Q2 '222022-06-3012K
Q1 '222022-03-315K
Q4 '212021-12-3127K
Q3 '212021-09-3024K
Q2 '212021-06-3037K
Q1 '212021-03-3156K

Gross Profit Quarterly

PeriodEndingGross Profit
Q4 '232023-12-3155K
Q3 '232023-09-3034K
Q2 '232023-06-304K
Q1 '232023-03-319K
Q4 '222022-12-317K
Q3 '222022-09-304K
Q2 '222022-06-306K
Q1 '222022-03-314K
Q4 '212021-12-3126K
Q3 '212021-09-3022K
Q2 '212021-06-3024K
Q1 '212021-03-3153K
Q4 '202020-12-31153K
Q3 '202020-09-3052K
Q2 '202020-06-3042K
Q1 '202020-03-3188K
Q4 '192019-12-31470K
Q3 '192019-09-30362K
Q2 '192019-06-30327K
Q1 '192019-03-31325K

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-6.8M
Q4 '252025-12-31-6.2M
Q3 '252025-09-30-6.4M
Q2 '252025-06-30-5.6M
Q1 '252025-03-31-5.9M
Q4 '242024-12-31-5.5M
Q3 '242024-09-30-5.3M
Q2 '242024-06-30-3.9M
Q1 '242024-03-31-2.3M
Q4 '232023-12-31241K
Q3 '232023-09-30-1.5M
Q2 '232023-06-30-945K
Q1 '232023-03-31-962K
Q4 '222022-12-31-1.8M
Q3 '222022-09-30-1.6M
Q2 '222022-06-30-1.6M
Q1 '222022-03-31-2.1M
Q4 '212021-12-31-1.9M
Q3 '212021-09-30-1.7M
Q2 '212021-06-30-2.2M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-6.4M
Q1 '262026-03-31-6.9M
Q4 '252025-12-31-3.3M
Q3 '252025-09-30-4.6M
Q2 '252025-06-30-6.4M
Q1 '252025-03-31-4.8M
Q4 '242024-12-31-2.7M
Q3 '242024-09-301.4M
Q2 '242024-06-305.2M
Q1 '242024-03-31-15M
Q4 '232023-12-311.1M
Q3 '232023-09-301.8M
Q2 '232023-06-30808K
Q1 '232023-03-311.7M
Q4 '222022-12-31-2.7M
Q3 '222022-09-30-2.4M
Q2 '222022-06-30-2.6M
Q1 '222022-03-31-2.7M
Q4 '212021-12-31-2.2M
Q3 '212021-09-30-2M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q4 '232023-12-311K
Q3 '232023-09-3033K
Q2 '232023-06-305K
Q1 '232023-03-311K
Q4 '222022-12-311K
Q3 '222022-09-305K
Q2 '222022-06-306K
Q1 '222022-03-311K
Q4 '212021-12-311K
Q3 '212021-09-302K
Q2 '212021-06-3013K
Q1 '212021-03-313K
Q4 '202020-12-315K
Q3 '202020-09-3017K
Q2 '202020-06-303K
Q1 '202020-03-311K
Q4 '192019-12-3179K
Q3 '192019-09-3049K
Q2 '192019-06-3053K
Q1 '192019-03-3163K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-6.7M
Q1 '262026-03-31-4.6M
Q4 '252025-12-31-6M
Q3 '252025-09-30-3.9M
Q2 '252025-06-30-3.8M
Q1 '252025-03-31-4.3M
Q4 '242024-12-31-4.6M
Q3 '242024-09-30-3M
Q2 '242024-06-30-8M
Q1 '242024-03-31-1.6M
Q4 '232023-12-31121K
Q3 '232023-09-30-1M
Q2 '232023-06-30-864K
Q1 '232023-03-31-709K
Q4 '222022-12-31-1.3M
Q3 '222022-09-30-1.2M
Q2 '222022-06-30-1.7M
Q1 '222022-03-31-1.6M
Q4 '212021-12-31-1.6M
Q3 '212021-09-30-1.9M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-6.7M
Q1 '262026-03-31-4.6M
Q4 '252025-12-31-6M
Q3 '252025-09-30-3.9M
Q2 '252025-06-30-3.8M
Q1 '252025-03-31-4.3M
Q4 '242024-12-31-4.6M
Q3 '242024-09-30-3M
Q2 '242024-06-30-8M
Q1 '242024-03-31-1.6M
Q3 '232023-09-30-1.1M
Q4 '202020-12-31-1.6M
Q3 '202020-09-30-1.9M
Q2 '202020-06-30-2.2M
Q1 '202020-03-31-2.1M
Q4 '192019-12-31-2.7M
Q3 '192019-09-30-2.6M
Q2 '192019-06-30-2.9M
Q1 '192019-03-31-2.6M
Q4 '182018-12-31-2M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3016.4M
Q1 '262026-03-3112M
Q3 '252025-09-3010.3M
Q2 '252025-06-3010M
Q1 '252025-03-319.8M
Q3 '242024-09-3010.8M
Q2 '242024-06-3010.2M
Q1 '242024-03-312.8M
Q3 '232023-09-307.6M
Q2 '232023-06-307.4K
Q1 '232023-03-318.6M
Q3 '222022-09-3037.9K
Q2 '222022-06-3037.9K
Q1 '222022-03-3137.9M
Q3 '212021-09-3037.9M
Q2 '212021-06-3037.9K
Q1 '212021-03-3137.7M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-1.89
Q1 '262026-03-31-2.00
Q4 '252025-12-31-1.91
Q3 '242024-09-30-4.58
Q2 '242024-06-30-4.48
Q1 '212021-03-31-0.27
Q4 '202020-12-31-0.29
Q3 '202020-09-30-0.30
Q2 '202020-06-30-0.32
Q1 '202020-03-31-0.33
Q4 '192019-12-31-0.34
Q3 '192019-09-30-0.35
Q2 '192019-06-30-0.32
Q1 '192019-03-31-0.30
Q4 '182018-12-31-0.22